Molecular diagnostic company DioGenix has released clinical validation data for its next-generation sequencing-based multiple sclerosis test, MS Precise.

The Gaithersburg, Md.-based company launched a blinded, multi-site prospective trial of its test in the beginning of 2013, evaluating patients without a diagnosis but who had some level of clinical presentation — either suspected myelination or multiple sclerosis-like presentations in their MRIs or cerebrospinal fluid, DioGenix CEO Larry Tiffany told Clinical Sequencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.